Atara Biotherapeutics Changes Fiscal Year End
Ticker: ATRA · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: fiscal-year-change, reporting
Related Tickers: ATRA
TL;DR
ATRA changed its fiscal year end to Dec 31. No other major news.
AI Summary
Atara Biotherapeutics, Inc. filed an 8-K on December 23, 2024, reporting a change in its fiscal year end to December 31st. This filing does not appear to contain any new financial statements or exhibits beyond the standard reporting requirements.
Why It Matters
A change in fiscal year end can impact reporting schedules and financial comparisons for investors. This filing indicates a shift in Atara's financial reporting calendar.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new material financial information or significant business events.
Key Players & Entities
- Atara Biotherapeutics, Inc. (company) — Registrant
- December 20, 2024 (date) — Date of earliest event reported
- December 31 (date) — New Fiscal Year End
- Delaware (jurisdiction) — State of Incorporation
- 001-36548 (identifier) — SEC File Number
- 46-0920988 (identifier) — IRS Employer Identification No.
- 2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, California 91320 (address) — Principal Executive Offices
- (805) 623-4211 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a change in Atara Biotherapeutics, Inc.'s fiscal year end.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 20, 2024.
What is the new fiscal year end for Atara Biotherapeutics, Inc.?
The new fiscal year end for Atara Biotherapeutics, Inc. is December 31.
In which state is Atara Biotherapeutics, Inc. incorporated?
Atara Biotherapeutics, Inc. is incorporated in Delaware.
What is the address of Atara Biotherapeutics, Inc.'s principal executive offices?
The address of Atara Biotherapeutics, Inc.'s principal executive offices is 2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, California 91320.
Filing Stats: 670 words · 3 min read · ~2 pages · Grade level 12.9 · Accepted 2024-12-23 16:00:28
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Mar
Filing Documents
- d480921d8k.htm (8-K) — 27KB
- d480921dex31.htm (EX-3.1) — 188KB
- 0001193125-24-284167.txt ( ) — 382KB
- atra-20241220.xsd (EX-101.SCH) — 3KB
- atra-20241220_lab.xml (EX-101.LAB) — 18KB
- atra-20241220_pre.xml (EX-101.PRE) — 11KB
- d480921d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 3.1 Third Amended and Restated Bylaws of Atara Biotherapeutics, Inc. dated December 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATARA BIOTHERAPEUTICS, INC. Date: December 23, 2024 By: /s/ AnhCo Nguyen AnhCo Nguyen, Ph.D. President and Chief Executive Officer